Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Abboud

Orthopaedic Surgery Philadelphia, PA Medical Doctor

NPI 1588608731 CMS profile 253372

1 Crescent Dr Ste 401, Philadelphia, PA 19112

Open in the dashboard

General payments

$3,912,584

1,204 records reported · program years 2019–2025

Research payments

$2,646

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$102,968

3 holdings reported · through program year 2025

Research they led as principal investigator

$121,901 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Joseph Abboud of Philadelphia, PA is reported in the CMS Open Payments database as having received $3,912,584 across 1,204 general payments and $2,646 in research payments paid to them. Separately, studies naming them as principal investigator received $121,901 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $102,968 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,313,543 236
2024 General $615,917 198
2023 General $673,509 226
2022 General $454,850 206
2021 General $333,494 114
2020 General $202,006 58
2019 General $319,265 166
2019 Research $2,646 1
2025 Ownership $101,620 1
2020 Ownership $674 1
2019 Ownership $674 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Abboud
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Joseph Abboud were reported at $1,313,543. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Joseph Abboud Orthopaedic Surgery median Middle half National median
2019 $319,265 $644 $140–$2,844 $163
2020 $202,006 $312 $75–$1,860 $114
2021 $333,494 $520 $117–$2,495 $132
2022 $454,850 $598 $128–$2,731 $149
2023 $673,509 $461 $128–$2,264 $160
2024 $615,917 $497 $134–$2,475 $164
2025 $1,313,543 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Encore Medical, LP $2,152,593 499 payments
  2. Zimmer Biomet Holdings, Inc. $1,281,620 428 payments
  3. restor3d, inc. $191,712 16 payments
  4. Stryker Corporation $130,537 87 payments
  5. Integra LifeSciences Corporation $59,232 9 payments
  6. Globus Medical, Inc. $32,328 41 payments
  7. Pacira Pharmaceuticals Incorporated $22,987 14 payments
  8. Insight Medical Systems, Inc. $17,770 11 payments
  9. Trice Medical, Inc. $10,144 8 payments
  10. Smith+Nephew, Inc. $3,592 8 payments
  11. Other $10,070 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,945,557 469 payments
  2. Royalty or License $1,652,475 109 payments
  3. Education $225,481 83 payments
  4. Travel and Lodging $64,413 188 payments
  5. Food and Beverage $21,629 353 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,029 2 payments
Products named General payments · program years 2019–2025
  1. DJO SURGICAL Joint Implants $1,324,053 154 payments
  2. DJO SURGICAL Joint Implants $851,968 152 payments
  3. DJO SURGICAL Joint Implants $565,843 9 payments
  4. DJO Surgical AltiVate Anatomic System Joint Implants $345,983 117 payments
  5. DJO Surgical AltiVate Anatomic System Joint Implants $239,586 32 payments
  6. Juggerknotless Soft Anchor $64,610 46 payments
  7. DJO Surgical AltiVate Reverse $55,398 29 payments
  8. mymobility Platform $53,400 9 payments
  9. INSPACE $53,103 42 payments
  10. TSSM - TOTAL SHOULDER SYSTEM METAL $52,529 8 payments
  11. Other $578,264 508 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Encore Medical, LP $2,646 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

50

Median for Orthopedic Surgery: 203

Drug cost

$176

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 37 $133
Tramadol Hcl Generic 13 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$150,843

Of which drugs: $290

Medicare patients

336

Average age 73

Services billed

1,564

185 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 74%
High blood pressure 71%
Ischemic heart disease 29%
Diabetes 24%
Osteoporosis 21%
Cancer 18%
Depression 17%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 47 396 $290

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TZIELD
$99 — —
XARELTO
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record